All In Biotech

Drug Trial Radar · NCT01406548

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

Last checked: Nov 19, 2026Latest source record: Sep 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Jul 2011

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
Collaborators
Mereo BioPharma; Novartis
First posted
Aug 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens. This information will permit a comparison of the possible risks and benefits of different dosing regimens of the study drug to enable optimal doses and dose intervals to be tested in subsequent studies.

Conditions

  • Osteopenia
  • Osteoporosis

Interventions

  • BPS804 20mg/KgDrug

  • Placebo to 20mg/Kg BPS804Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to month 9 in bone mineral density at the lumbar spine for the individual BPS804 groups and pooled placebo arms.Time frame: 9 months
  2. The number (percent) of subjects experiencing adverse events or serious adverse eventsTime frame: 9 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Anaheim, California

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Berlin, New Jersey

  • Novartis Investigative Site

    Duncansville, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.